214 related articles for article (PubMed ID: 19863778)
1. Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down.
Costa JL; Eijk PP; van de Wiel MA; ten Berge D; Schmitt F; Narvaez CJ; Welsh J; Ylstra B
BMC Genomics; 2009 Oct; 10():499. PubMed ID: 19863778
[TBL] [Abstract][Full Text] [Related]
2. 1alpha,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma.
Wu W; Zhang X; Zanello LP
Cancer Lett; 2007 Aug; 254(1):75-86. PubMed ID: 17412493
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic Response to 1,25-Dihydroxyvitamin D in Human Fibroblasts with or without a Functional Vitamin D Receptor (VDR): Novel Target Genes and Insights into VDR Basal Transcriptional Activity.
Costa PLF; França MM; Katayama ML; Carneiro ET; Martin RM; Folgueira MAK; Latronico AC; Ferraz-de-Souza B
Cells; 2019 Apr; 8(4):. PubMed ID: 30959822
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor.
An BS; Tavera-Mendoza LE; Dimitrov V; Wang X; Calderon MR; Wang HJ; White JH
Mol Cell Biol; 2010 Oct; 30(20):4890-900. PubMed ID: 20733005
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.
Pervin S; Hewison M; Braga M; Tran L; Chun R; Karam A; Chaudhuri G; Norris K; Singh R
PLoS One; 2013; 8(1):e53287. PubMed ID: 23341935
[TBL] [Abstract][Full Text] [Related]
6. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM; McEleney K; Welsh J
Mol Cell Endocrinol; 2003 Feb; 200(1-2):67-80. PubMed ID: 12644300
[TBL] [Abstract][Full Text] [Related]
7. A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Izkhakov E; Sharon O; Knoll E; Aizic A; Fliss DM; Kohen F; Stern N; Somjen D
J Steroid Biochem Mol Biol; 2018 Sep; 182():81-86. PubMed ID: 29702263
[TBL] [Abstract][Full Text] [Related]
8. Stable expression of human VDR in murine VDR-null cells recapitulates vitamin D mediated anti-cancer signaling.
Keith ME; LaPorta E; Welsh J
Mol Carcinog; 2014 Apr; 53(4):286-99. PubMed ID: 23681781
[TBL] [Abstract][Full Text] [Related]
9. Modeling vitamin D actions in triple negative/basal-like breast cancer.
LaPorta E; Welsh J
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():65-73. PubMed ID: 24239860
[TBL] [Abstract][Full Text] [Related]
10. VDR in salivary gland homeostasis and cancer.
DeSantis KA; Robilotto SL; Matson M; Kotb NM; Lapierre CM; Minhas Z; Leder AA; Abdul K; Facteau EM; Welsh J
J Steroid Biochem Mol Biol; 2020 May; 199():105600. PubMed ID: 31958633
[TBL] [Abstract][Full Text] [Related]
11. Actions of 1,25(OH)2-vitamin D3 on the cellular cycle depend on VDR and p38 MAPK in skeletal muscle cells.
Irazoqui AP; Boland RL; Buitrago CG
J Mol Endocrinol; 2014 Dec; 53(3):331-43. PubMed ID: 25316911
[TBL] [Abstract][Full Text] [Related]
12. Comparative regulation of gene expression by 1,25-dihydroxyvitamin D3 in cells derived from normal mammary tissue and breast cancer.
Beaudin SG; Robilotto S; Welsh J
J Steroid Biochem Mol Biol; 2015 Apr; 148():96-102. PubMed ID: 25239595
[TBL] [Abstract][Full Text] [Related]
13. IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer.
Abdel-Mohsen MA; Abo Deif SM; Abou-Shamaa LA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2267-2273. PubMed ID: 31450894
[TBL] [Abstract][Full Text] [Related]
14. Resistance to 1,25D-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor.
Garay E; Donnelly R; Wang X; Studzinski GP
J Cell Physiol; 2007 Dec; 213(3):816-25. PubMed ID: 17520689
[TBL] [Abstract][Full Text] [Related]
15. SIRT1 enzymatically potentiates 1,25-dihydroxyvitamin D
Sabir MS; Khan Z; Hu C; Galligan MA; Dussik CM; Mallick S; Stone AD; Batie SF; Jacobs ET; Whitfield GK; Haussler MR; Heck MC; Jurutka PW
J Steroid Biochem Mol Biol; 2017 Sep; 172():117-129. PubMed ID: 28636886
[TBL] [Abstract][Full Text] [Related]
16. Function of the vitamin D endocrine system in mammary gland and breast cancer.
Welsh J
Mol Cell Endocrinol; 2017 Sep; 453():88-95. PubMed ID: 28579119
[TBL] [Abstract][Full Text] [Related]
17. The Tumor Suppressor FBW7 and the Vitamin D Receptor Are Mutual Cofactors in Protein Turnover and Transcriptional Regulation.
Salehi-Tabar R; Memari B; Wong H; Dimitrov V; Rochel N; White JH
Mol Cancer Res; 2019 Mar; 17(3):709-719. PubMed ID: 30606768
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells.
Egan JB; Thompson PA; Vitanov MV; Bartik L; Jacobs ET; Haussler MR; Gerner EW; Jurutka PW
Mol Carcinog; 2010 Apr; 49(4):337-52. PubMed ID: 20043299
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm.
Trivedi T; Zheng Y; Fournier PGJ; Murthy S; John S; Schillo S; Dunstan CR; Mohammad KS; Zhou H; Seibel MJ; Guise TA
Oncotarget; 2017 Apr; 8(16):26687-26701. PubMed ID: 28460457
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between the peroxisome proliferator-activated receptor γ (PPARγ) and the vitamin D receptor (VDR) in human breast cancer cells: PPARγ binds to VDR and inhibits 1α,25-dihydroxyvitamin D3 mediated transactivation.
Alimirah F; Peng X; Yuan L; Mehta RR; von Knethen A; Choubey D; Mehta RG
Exp Cell Res; 2012 Nov; 318(19):2490-7. PubMed ID: 22884583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
